Radisson Hotel Narita
286-0221 Chiba Tomisato- shi Nakaei
650-35 Tokyo, Japan
Phone : 1 (702) 988 2320
Toll Free: 1800–883-8082
Email: cardiology@magnusmeetings.com
October 24-25, 2019 | Tokyo, Japan

Mekhman N Mamedov

Keynote Speaker at Cardiology Conferences- Mekhman N Mamedov
Mekhman N Mamedov
National Research Center for Preventive Medicine, Russia
Title : Features of clinical and biochemical parameters, quality of life and prognosis of patients with CAD in combination with type 2 diabetes and COPD


A cohort study included 220 patients of both sexes aged 39 to 69 years old. In order to study the association of CAD with other NCD, the patients were divided into 3 groups: patients with CAD without comorbidity (group I, n = 80), with CAD and type 2 diabetes (group II, n = 70) and CAD with COPD (group III, n = 70). All patients underwent: history taking, ECG registration at rest, echoCG, and biochemical blood tests. Quality of life was assessed using the international questionnaire EQ-5D and the analog scale EQVas. To determine the prognosis of 10-year survival, the Charlson comorbidity index was used.

Results. The average SBP was the highest among patients with CHD and type 2 diabetes. According to EchoCG in the groups of patients with CAD with comorbidity, the average values ??of the interventricular septum thickness and left ventricular myocardial mass index were statistically significantly higher compared with the group of patients without comorbidity (117.03 ± 19.59 g (group II) vs 108.73 ± 27.44 g ( Group III) vs 99.15 ± 13.48 g (group I) - p <0.01). The level of triglycerides was highest in the group of CHD and type 2 diabetes, while other lipid metabolism indicators were comparable in all three groups. Evaluation of psychometric and physical parameters of quality of life showed that the severity of discomfort and decrease in mobility were significantly higher in groups with COPD and type 2 diabetes. According to the EQVas visual analogue scale, in the groups of patients with CAD and comorbidity, self-assessment of health was lower (p <0.01). An analysis of the 10-year survival prognosis for the Charlson comorbidity index showed that in both groups with comorbidity, this indicator was high compared with the control group, but in patients with CAD in combination with type 2 diabetes, its severity was 20% higher than in the group with COPD

Conclusion. Thus, comorbidity of CAD with type 2 diabetes and COPD is associated with a deterioration in the quality of life and a predicted survival rate for the comorbidity index. Patients with CAD and type 2 diabetes showed the worst indicators of prognosis, quality of life and clinical and biochemical parameters.


Professor Mehman Mamedov graduated from the I.M. Sechenov Moscow Medical Academy in 1993.  He continued his medical education as a cardiology intern at the Medical Centre for the President of the Russian Federation, at the Central Clinical Hospital.
Dr Mamedov holds a PhD degree (1997) from the National Research Centre for Preventive Medicine. His thesis was entitled, “The components of the metabolic syndrome in arterial hypertension patients”. In 2001, he wrote a higher doctorate thesis on, “The clinical and biochemical peculiarities and approaches to the pharmaceutical management of the metabolic syndrome”.
Under Dr Mamedov’s supervision, 9 PhD and 1 higher doctorate theses were achieved.
Today Dr. Mamedov is Head of the Laboratory for Interdisciplinary Approaches on the Prevention of Chronic Non-communicable Diseases at the National Research Centre for Preventive Medicine; Vice-President of the Cardioprogress Foundation, and Deputy Chief Editor of the International Heart and Vascular Disease Journal. He is also  member of the Board of the Russian Society of Cardiology and Head of the Diabetes and CVD Section, member of the editorial board of the journals Cardiology and Cardiovascular Prevention and Therapy and the organizer of the annual International Forum of Cardiology and Internal medicine  in Moscow and 4 regional conferences.
Dr Mamedov M. is an author of more than 300 scientific works, including 14 monographs and books, some of which were published in English. His Hirsch index is 28, Scopus and Web of science index -5.   
The scientific interests of Dr Mamedov encompass cardiometabolic disorders, disorders of lipid metabolism, men's health problems, prognosis and correction of cardiovascular risk, early markers of atherosclerosis, prediabetes and diabetes, epidemiology of cardiovascular disease and chronic non-inflectional diseases.